SIBO, IMO & Gut Motility

If you have spent any time researching small intestinal bacterial overgrowth (SIBO), you have probably noticed that the conversation feels both crowded and confused. Three different breath tests disagree with each other. Several treatment paths have evidence behind them. Diet recommendations contradict each other. And now the condition itself is getting reorganized as we understand more about the subtypes.

What follows is the version I walk through with patients in clinic. What SIBO and intestinal methanogen overgrowth (IMO) are. Why the migrating motor complex matters more than people realize. How testing works (and when to skip it). The three evidence-backed treatment paths. What to eat without burning down your microbiome. And the parts of the picture that get less attention: stress, hormones, and why so many cases relapse.

What SIBO Is, and What IMO Is#

Small intestinal bacterial overgrowth is what it sounds like. Too many bacteria are living in a part of the gut that is supposed to stay relatively sparse. The small intestine handles digestion and nutrient absorption. The large intestine is where the bulk of your microbial population lives. When bacteria from the colon drift up, or when motility slows enough to let small numbers of small-intestinal bacteria multiply unchecked, you end up fermenting your food before your body has finished digesting it. That fermentation produces gas. The gas produces the symptoms patients describe when they walk in: bloating that worsens through the day, abdominal pain, irregular stools, food reactions, and a sense that something is off no matter what they eat.

Until recently, all of this was called SIBO regardless of which organism was involved. We now distinguish two patterns:

• Bacterial SIBO is overgrowth of bacteria, usually producing hydrogen gas. The clinical picture tends toward diarrhea-predominant or mixed presentations.
• Intestinal methanogen overgrowth (IMO) is an overgrowth of methanogenic archaea, most commonly Methanobrevibacter smithii. Methanogens are not bacteria at all. They consume hydrogen and produce methane. The clinical picture is often constipation-predominant.

A 2024 systematic review and meta-analysis of 1,293 patients with IMO found significantly higher rates of constipation compared to controls (47% vs 38%, OR 2.04, p < 0.0001) and lower rates of diarrhea [1]. The renaming from "methane SIBO" to IMO reflects the basic biology. Methanogens are not bacteria. They are not confined to the small intestine. And their treatment approach differs enough from bacterial SIBO to deserve a separate label [2].

A third pattern, hydrogen sulfide overgrowth, is increasingly recognized. Hydrogen-consuming bacteria can convert hydrogen into hydrogen sulfide before it leaves the body. On a standard 2-gas breath test this looks like a negative result, since the test does not measure H2S. The clinical picture often includes diarrhea and a distinctive sulfur smell [3].

The Migrating Motor Complex#

If you only learn one piece of physiology about gut motility, learn this one. Between meals, your gut runs a cleanup cycle called the migrating motor complex, or MMC. The MMC is a wave of contractions that sweeps through the small intestine roughly every 90 to 120 minutes when you are not actively digesting. It pushes residual food, bacteria, and debris from the upper small intestine toward the large intestine, keeping the small bowel relatively clean. This is the same housekeeping mechanism that explains how a swallowed coin eventually passes through.

When the MMC slows or stops working well, bacteria have more time to linger and multiply. That is the central pathophysiology behind recurrent SIBO. You can clear an overgrowth with antimicrobials and watch it come back within months because the underlying motility problem was never addressed.

A short list of things that slow the MMC:

• Frequent grazing or eating every one to two hours, which keeps the gut in digestive mode and prevents the cleanup cycle from initiating
• Diabetes and post-infectious motility damage following a documented gastrointestinal infection
• Connective tissue disorders, particularly Ehlers-Danlos syndrome and other hypermobility spectrum disorders
• Hormonal influences, since estrogen has a modest motility-slowing effect and cycle-related symptom shifts are common
• Chronic stress and dysautonomia, both of which dysregulate the autonomic input to the gut
• Opioid use, which is profoundly motility-suppressing
• Surgical changes such as gastric bypass or colectomy

Any sustainable SIBO treatment plan has to include MMC support. Otherwise you are clearing the overgrowth and waiting for it to come back.

Why SIBO Comes Back#

A meaningful proportion of SIBO patients relapse within months of successful treatment [4]. The reason is rarely treatment failure in the technical sense. The bacteria were eradicated from a small intestine whose underlying motility had not changed. Slow transit creates the conditions for overgrowth. Eradicating the overgrowth without restoring transit is like cleaning a clogged drain without fixing the slope of the pipe.

Prokinetics are the bridge between eradication and durable recovery. Prescription options include low-dose erythromycin (a motilin agonist used off-label), prucalopride (a 5-HT4 agonist), and several PAMORAs (peripherally-acting mu-opioid antagonists used in opioid-induced dysmotility). Herbal options include ginger and artichoke leaf, both of which have lower side-effect profiles and are often tried first when patients tolerate them.

Beyond prokinetics, three habits change outcomes:

• Spacing meals three to four hours apart and giving the gut at least one fasting window long enough for several MMC cycles to run
• Avoiding constant snacking, which keeps the gut in digestive mode and silences the MMC
• Treating the underlying drivers (stress, hormones, opioid use, hypothyroidism, comorbid conditions)

These are not glamorous. They are also the difference between repeated treatment courses and a stable result.

Testing#

Three ways to test for SIBO exist. The gold standard is a jejunal aspirate culture, where a sample of small-intestinal contents is collected during endoscopy and sent for culture. It is invasive, expensive, and rarely done outside specific clinical contexts.

Most patients are tested with breath tests instead. Breath tests rely on bacteria fermenting a sugar substrate and producing gases that diffuse into the bloodstream and are exhaled. The two common substrates are glucose and lactulose:

• Glucose breath test. Glucose is rapidly absorbed in the proximal two-thirds of the small intestine. The test catches overgrowth in that region well but misses overgrowth in the distal small intestine. Specificity is approximately 83%, sensitivity around 55% [5].
• Lactulose breath test. Lactulose is not absorbed by the human gut, so it travels the full length of the small intestine and into the colon. This makes the test more sensitive to distal overgrowth, but the colonic passage produces confounding readings that lower specificity. Specificity is approximately 71%, sensitivity around 42% [5].

Most current guidance and most clinicians I know lean toward the glucose breath test as the more reliable single option. Lactulose still has a role for suspected distal overgrowth.

A third gas matters: hydrogen sulfide. Standard 2-gas breath tests measure hydrogen and methane. If hydrogen-consuming bacteria are converting hydrogen into hydrogen sulfide before it exits the body, the test reads negative even in active overgrowth. Three-gas testing is now available from specialty labs and is worth considering for any patient with a strong clinical picture and a negative 2-gas test [3, 6].

When to skip testing entirely: if the clinical presentation is classic, the differential is narrow, and you have rapport with your clinician, presumptive treatment is reasonable. The AGA's 2020 clinical practice update acknowledges that SIBO testing is imperfect and that empirical treatment based on clinical pattern is appropriate in many cases [4].

Treatment Options#

Three evidence-backed treatment paths exist.

Rifaximin (Xifaxan). A non-systemically-absorbed antibiotic taken for two weeks. Rifaximin has the strongest published evidence base for SIBO and is endorsed in the AGA practice update [4, 5]. Two practical caveats: it is expensive out-of-pocket (often several thousand dollars uncovered), and insurance coverage is inconsistent and frequently requires step therapy through other antibiotics first. For methane-predominant cases, rifaximin is sometimes combined with neomycin since rifaximin alone has limited activity against methanogens.

Herbal antimicrobials. Typically a four-week course using two or more agents to prevent resistance. Common options include berberine, oregano oil, neem, garlic-derived allicin, and several others. The four-week duration matters. The multi-agent strategy matters. A trial of berberine or oregano alone, especially a long-term trial, often selects for resistant bacteria rather than eradicating the overgrowth. When I run this protocol with a patient, we hit it with two or more agents simultaneously and we cycle agents if we are repeating courses.

Elemental diet. A 14-day liquid diet of fully pre-digested macronutrients: amino acids in place of proteins, medium-chain triglycerides in place of fats, simple sugars in place of complex carbohydrates. The mechanism is starvation. Nutrients are absorbed in the upper small intestine before bacteria can reach them. It works. It is also unpleasant, expensive in commercial form, and contraindicated in fungal overgrowth since the simple sugars feed candida. Homemade ketogenic-style versions exist for patients with co-occurring fungal issues.

Choosing among these is patient-specific. Cost, sensitivity to medications, prior antibiotic history, severity, and the gas profile (hydrogen, methane, or hydrogen sulfide) all influence the decision. Patients who are severely sensitive to rapid microbial die-off, common in MCAS, mold-illness, and other complex chronic presentations, often need a gentler stepwise approach than any of the above three.

What to Eat (and Why I Am Cautious About Long-Term Low-FODMAP)#

The low-FODMAP diet reduces the fermentable substrates that small-intestinal bacteria use to produce gas. It works for symptom control, sometimes dramatically. Most patients feel a meaningful reduction in bloating and pain within days.

The complication is what happens when low-FODMAP becomes the long-term diet. FODMAPs are the precursors to short-chain fatty acids in the colon, which support immune regulation, oral tolerance to food, and microbial diversity. Years on a strict low-FODMAP diet narrow the colonic microbiome and can worsen food reactivity over time. The diet is a short-term tool, not a destination.

Two clinical points patients often miss:

• During active antimicrobial treatment, low-FODMAP eating is counterproductive. You want the bacteria metabolically active so the antimicrobials can reach them. Save the low-FODMAP phase for symptom management before treatment, or for a brief transition period after.
• Therapeutic fasting, in the form of extended overnight fasts of 12 to 14 hours, lets the MMC do its job and is often a better long-term strategy than restrictive eating.

A randomized controlled trial of low-FODMAP eating in IBS patients found urinary histamine dropped roughly eightfold compared to a high-FODMAP diet [7], which suggests the diet's symptom effects extend beyond the gas-fermentation mechanism into broader immune and inflammatory pathways.

Stress, Hormones, and Other Layers#

Recurrent SIBO is rarely a single-cause condition. The patients who do best long-term are the ones whose treatment plan addresses the layers underneath the overgrowth.

Stress. The autonomic nervous system regulates motility. Chronic stress shifts the body toward sympathetic dominance, which slows the MMC and impairs digestion. Vagal-tone work, paced breathing, and the broader nervous-system regulation strategies that show up in the MCAS hub apply here too.

Hormones. Estrogen has a modest motility-slowing effect, and many women notice their SIBO symptoms cycle with their menstrual phase. Hypothyroidism slows transit substantially and is worth ruling out in any chronic constipation or recurrent SIBO picture.

Comorbid conditions. SIBO travels often with hypermobility spectrum disorders (especially Ehlers-Danlos), POTS, MCAS, and post-infectious IBS following a documented gastrointestinal infection. When one of these is present, SIBO rarely resolves permanently without addressing the underlying condition.

Medications. Proton pump inhibitors, opioids, and chronic anticholinergics all increase SIBO risk through different mechanisms. Reviewing the medication list is part of the workup.

What Recovery Looks Like#

For a first-time, uncomplicated SIBO case, a single treatment course plus motility support often does the job. For a chronic relapsing case in a complex patient, which is most of what my clinic looks like, recovery is layered. The pattern that works most often:

1. A short-term symptom intervention (low-FODMAP or fasting structure, simple antihistamine support if MCAS is also present)
2. A targeted antimicrobial course matched to the gas profile
3. A prokinetic phase, often three to six months long, to retrain the MMC
4. Stepwise reintroduction of fiber and FODMAP-containing foods
5. Continued attention to the underlying drivers: sleep, stress, hormones, medications, comorbid conditions

The patients who do best are the ones who treat the relapse curve as information, not failure. A relapse means there is still an underlying driver. The next round of work is to find it.

If you want a more structured walk-through of testing, treatment phases, and the motility work that keeps overgrowth from coming back, the SIBO Guide covers the same material I take patients through in clinic.

References#

1. Mehravar S, Takakura W, Wang J, Pimentel M, Nasser J, Rezaie A. Symptom Profile of Patients With Intestinal Methanogen Overgrowth: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2024;23(7):1111-1122. doi:10.1016/j.cgh.2024.07.020
2. Takakura W, Pimentel M. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome - An Update. Front Psychiatry. 2020;11:664. doi:10.3389/fpsyt.2020.00664
3. Carbonero F, Benefiel AC, Gaskins HR. Contributions of the microbial hydrogen economy to colonic homeostasis. Nat Rev Gastroenterol Hepatol. 2012;9(9):504-518. doi:10.1038/nrgastro.2012.85
4. Quigley EMM, Murray JA, Pimentel M. AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review. Gastroenterology. 2020;159(4):1526-1532. doi:10.1053/j.gastro.2020.06.090
5. Rezaie A, Pimentel M, Rao SS. How to Test and Treat Small Intestinal Bacterial Overgrowth: an Evidence-Based Approach. Curr Gastroenterol Rep. 2016;18(2):8. doi:10.1007/s11894-015-0482-9
6. Zafar H, Jimenez B, Schneider A. Small intestinal bacterial overgrowth: current update. Curr Opin Gastroenterol. 2023;39(6):522-528. doi:10.1097/MOG.0000000000000971
7. McIntosh K, Reed DE, Schneider T, et al. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. Gut. 2017;66(7):1241-1251. doi:10.1136/gutjnl-2015-311339
8. Rao SSC, Bhagatwala J. Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management. Clin Transl Gastroenterol. 2019;10(10):e00078. doi:10.14309/ctg.0000000000000078